ALTRENO LOTION

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

TRETINOIN

Disponibbli minn:

BAUSCH HEALTH, CANADA INC.

Kodiċi ATC:

D10AD01

INN (Isem Internazzjonali):

TRETINOIN

Dożaġġ:

0.05%

Għamla farmaċewtika:

LOTION

Kompożizzjoni:

TRETINOIN 0.05%

Rotta amministrattiva:

TOPICAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

CELL STIMULANTS AND PROLIFERANTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0112395001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2021-10-08

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALTRENO
TM
Tretinoin Lotion
Lotion with moisturizers 0.05% w/w
COMEDOLYTIC AGENT
BAUSCH HEALTH, CANADA INC.
2150 St-Elzear Blvd., West
Laval, Quebec H7L 4A8
Canada
DATE OF REVISION:
October 7, 2021
Submission Control No: 251922
_ _
_Pr_
_ALTRENO_
_TM_
_ – Product Monograph Page 2 of 28_
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
..........................................................................................................
2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics............................................................................................................
4
2
CONTRAINDICATIONS
...............................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................
4
4.2
Recommended Dose and Dosage Adjustment
.................................................... 4
4.4
Administration.....................................................................................................
5
5
OVERDOSAGE
...........................................................................................................
5
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING
........................ 6
7
WARNINGS AND PRECAUTIONS
..............................................................................
6
7.1
Special Populations
............................................................................................
7
7.1.1
Pregnant Women
...............................................................................